Drug Delivery Insights: Strategies for Solubility and Bioavailability Enhancement of Poorly Soluble Drugs - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Drug Delivery Insights: Strategies for Solubility and Bioavailability Enhancement of Poorly Soluble Drugs
Kurt Nielsen, PhD, chief technology officer and senior vice-president of R&D at Catalent Pharma Solutions, discusses strategies for solubility and bioavailability enhancement of poorly water-soluble drugs.

Pharmaceutical Technology
Volume 37, Issue 6

Improving the oral absorption and bioavailability of poorly soluble drugs is crucial for pharmaceutical companies seeking to bring efficacious drugs to patients in dosing regimens and product forms that are easy to use, affordable, and facilitate patient compliance. To understand the extent of this challenge and the technologies for bioavailability/solubility enhancement, Pharmaceutical Technology partnered with the Catalent Applied Drug Delivery Institute in the second annual Catalent–Pharmaceutical Technology Landscape Drug Delivery Survey (see here for survey results). The study surveyed formulation scientists involved with oral product development in pharmaceutical companies in the United States, Canada, and Europe to understand their key concerns and the technologies used to resolve problems of solubility and bioavailability. The results showed that there are a myriad of technical concerns attendant to solubility/bioavailablity and many factors have to be taken into consideration in deciding which approach is optimal for a given API. In an editorial podcast, Kurt Nielsen, chief technology officer and senior vice-president of R&D for Catalent Pharma Solutions, provided insight into the technology challenges and solutions for bioavailability enhancement.

ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
FDASIA was signed into law two years ago. Where has the most progress been made in implementation?
Reducing drug shortages
Breakthrough designations
Protecting the supply chain
Expedited reviews of drug submissions
More stakeholder involvement
Reducing drug shortages
30%
Breakthrough designations
9%
Protecting the supply chain
39%
Expedited reviews of drug submissions
9%
More stakeholder involvement
13%
View Results
Jim Miller Outsourcing Outlook Jim Miller Health Systems Raise the Bar on Reimbursing New Drugs
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerThe Mainstreaming of Continuous Flow API Synthesis
Jill Wechsler Regulatory Watch Jill Wechsler Industry Seeks Clearer Standards for Track and Trace
Siegfried Schmitt Ask the Expert Siegfried SchmittData Integrity
Sandoz Wins Biosimilar Filing Race
NIH Translational Research Partnership Yields Promising Therapy
Clusters set to benefit from improved funding climate but IP rights are even more critical
Supplier Audit Program Marks Progress
FDA, Drug Companies Struggle with Compassionate Use Requests
Source: Pharmaceutical Technology,
Click here